Immunohistochemical analysis was carried out in vivo to investigate the effects of the combined PIM‐2 inhibitor SMI‐16a and PARP1 inhibitor ABT888 on multiple myeloma (MM). Here, PIM2 is linked to plasma cell myeloma.